The Wait is Over, Garth Brooks Returns to Radio with the Launch of The BIG 615 Exclusively on TuneIn
16.6.2023 08:00:00 CEST | Business Wire | Press Release
TuneIn, the world’s leader in live audio, announces the exclusive launch of The BIG 615 radio station from Garth Brooks’ SEVENS Radio Network.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230615074134/en/
Garth Brooks (Photo: Business Wire)
The BIG 615 offers listeners an authentic take on country music that offers up the biggest songs and the biggest artists today. “I believe that country music listeners want to hear the latest from George Strait followed by the latest from Luke Combs. The latest from Ashley McBryde followed by the latest from The Chicks,” said Garth Brooks.
Fans around the world can stream The BIG 615 for free only on TuneIn beginning today.
Storme Warren will be the official voice of The BIG 615. Millions and millions of country music fans start their day with Warren. He brings a passion for the format and vast knowledge of the genre to the station and will partner with Brooks to drive content. Warren will be joined by guest hosts on occasion, including Brooks and other industry stars.
“The BIG 615 station is purely for the love of country music,” Brooks continued. “We lean a bit more traditional at The BIG 615. We are proud of how the station sounds and want the entire world to hear what we think is the greatest format of all…Country Music.”
“Garth Brooks has an amazing vision for radio,” said Rich Stern, CEO of TuneIn. “At TuneIn, we are honored to work with an artist like Garth to build his vision and create an unduplicable experience for our listeners. We are even more excited to bring The BIG 615 to our global community of listeners, providing them with a one-of-a-kind destination to immerse themselves in the world of country music.”
“I LOVE the fact the station is coming from the home of Country Music,” Brooks adds. “Broadcasting from Music Row, the heart of Nashville and Country Music.”
SEVENS Radio is set to launch multiple stations on TuneIn this year, dedicated to country music and more, all curated and conceived by Garth Brooks and the SEVENS Radio Network…exclusively on TuneIn.
TuneIn is the world’s largest platform for live radio. It has over 75 million listeners across 122 countries to amplify country music around the world. The platform provides SEVENS Radio access to a truly global audience. TuneIn’s technology is integrated into 200 different vehicles and devices, so fans can listen on their phones, smart speakers or in their cars.
To view the full introduction video of The Big 615 from today’s launch please visit here.
To start streaming The BIG 615 today, visit TuneIn.com/garthbrooks or download the TuneIn App in the Apple App Store or Google Play for free. Or, ask your smart speaker to “Play The BIG 615.”
About TuneIn:
TuneIn, the world’s leader in live audio, brings together live sports, news, music, audiobooks, podcasts and radio from around the globe, empowering listeners to ‘hear’ what they love wherever ‘here’ might be. With more than 75 million monthly active users and distribution across 200 platforms and connected devices, TuneIn is one of the most widely used streaming audio platforms in the world. TuneIn Premium subscribers get exclusive access to commercial-free news from top networks like CNN, Fox News Radio, CSPAN, MSNBC, CNBC and Bloomberg, as well as live MLB, NFL, NHL and college sports programming and commercial-free music channels. For more information, please visit us at www.tunein.com or follow us on Facebook, Instagram or Twitter.
About Garth Brooks:
Garth Brooks just began a new residency, Garth Brooks/Plus ONE at The Colosseum at Caesars Palace. With 2023 sold out, 2024 dates are already on sale. Last year, Garth Brooks completed the three and a half year long Stadium Tour. It drew an average of more than 95 thousand people in each city it played and was seen by a cumulative audience of nearly three-million people. The tour ended in September when Garth played the fifth sold-out concert at Dublin, Ireland’s Croke Park. The five concerts were seen by over 400-thousand people.
In May 2021, Garth Brooks was one of five artists to receive one of the most prestigious honors an artist can receive, The Kennedy Center Honor. Garth is the first-ever seven-time recipient of the CMA Entertainer of the Year honor. Brooks is the first and only artist in history to receive nine Diamond Awards for the now nine diamond-certified albums at over 10 million album sales each. He remains the #1-selling solo artist in U.S. history, certified by the RIAA with 157 million album sales. He was awarded Country Touring Artist of the Decade at the 2021 Pollstar Awards. In March 2020, Garth received the esteemed Library of Congress Gershwin Prize for Popular Song. The event aired on PBS. He has received every accolade the recording industry can bestow on an artist.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230615074134/en/
Contact information
Media Contact For TuneIn:
Angela Petersen
SamsonPR
Angela@SamsonPR.com
Media Contact for Garth Brooks
Nancy Seltzer
Nancy Seltzer & Assoc. Inc
323-938-3562
nseltzer@nsapr.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom